Consecutively, imatinib, sorafenib, dasatinib, sunitinib and neutralizing PDGFR antibodies are being investigated in clinical trials in patients with human cancer, like recurrent ovarian carcinoma [70] or prostate cancer [107]. Here, PDGFRB is linked to ovarian carcinoma.